US pharmaceutical group Pfizer announced on Wednesday that it will collaborate with Evotec, a German life sciences specialist, to advance research in France.

This multi-year agreement, which includes a licensing option, will initially focus on early-stage research in the field of metabolic and infectious diseases.

This work will be carried out at Evotec's French sites, in particular at the Curie Campus in Toulouse, which boasts resources in high-throughput screening, in vitro and in vivo biology, proteomics and metabolomics.

In return, Evotec will receive funding from Pfizer to support its medical research activities, and will be entitled to milestone payments and royalties if the programs are successful.

In a press release, Pfizer explains that it hopes this research will lead to the development of new therapeutic approaches for the most common metabolic and infectious diseases, affecting millions of patients worldwide.

Both Pfizer and Evotec praise the quality of the French biopharmaceutical ecosystem, with the German company pointing out that it currently employs over 1,000 people at its French sites.

Copyright (c) 2024 CercleFinance.com. All rights reserved.